Idorsia Ltd header image

Idorsia Ltd

IDIA

Equity

ISIN CH0363463438 / Valor 36346343

SIX Swiss Exchange (2026-10-30)
CHF 4.47-2.44%

Idorsia Ltd
UMushroom community rating:

star star star star star
3.95 25 votes No rating yet
NegativeNeutralPositive

About company

Idorsia Ltd is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company aims to address significant unmet medical needs by advancing a diverse pipeline of drug candidates across various therapeutic areas. Idorsia's research and development efforts are concentrated on creating novel treatments that can improve patient outcomes. With a commitment to scientific excellence, the company leverages its expertise in drug discovery and development to bring new therapies to market. Headquartered in Switzerland, Idorsia operates with a global perspective, seeking to make a meaningful impact on healthcare through its innovative pharmaceutical solutions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

34.6%1Y
177%3Y
-76.3%5Y

Performance

69.3%1Y
100%3Y
84.8%5Y

Volatility

Market cap

1427 M

Market cap (USD)

Daily traded volume (Shares)

640,440

Daily traded volume (Shares)

1 day high/low

0.849 / 0.78

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.95

25 votes
Performance:
starstarstarstarstar
3.53
Innovation:
starstarstarstarstar
4.05
Society:
starstarstarstarstar
3.87
Nature:
starstarstarstarstar
3.60
Viktor Stockel
Switzerland, 22 Mar 2026
star star star star star
Overall a good company
Shana Locher
Switzerland, 22 Mar 2026
star star star star star
Idorsia is a high-risk biotech turnaround with strong innovation potential. Revenue is growing, but profitability remains negative and financing risks persist. Success depends heavily on pipeline execution and commercialization of key drugs.
Nicolas Allet
Switzerland, 21 Mar 2026
star star star star star
Innovative biotech with strong R&D pipeline, but weak financial performance and high cash burn. Success depends heavily on drug approvals and commercialization execution.

EQUITIES OF THE SAME SECTOR

Omnicell Inc
Omnicell Inc Omnicell Inc Valor: 1275961
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.62%USD 36.65
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc Valor: 25419823
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%USD 37.41
Trupanion Inc
Trupanion Inc Trupanion Inc Valor: 24738737
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.20%USD 30.13
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.43%SEK 276.80
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.45%SEK 490.20
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited Dr. Lal PathLabs Limited Valor: 30691066
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.37%INR 1,906.30
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.05%USD 16.03
Elekta AB
Elekta AB Elekta AB Valor: 613625
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.05%SEK 59.70
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.69%SEK 317.20
Essity AB
Essity AB Essity AB Valor: 36846754
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%SEK 279.50